Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y., Nov. 15, 2017

The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite^® technologies, including VelocImmune^® which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations                                         ARIVA.DE Börsen-Geflüster Werbung Weiter abwärts? Kurzfristig positionieren in Regeneron Pharmaceuticals MB9Z7H Ask: 1,14 Hebel: 18,11 mit starkem Hebel Zum Produkt MB82H5 Ask: 2,23 Hebel: 5,32 mit moderatem Hebel Zum Produkt Morgan Stanley Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: MB9Z7H,MB82H5,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen. Kurse Regeneron Pharmaceuticals 883,20 $ -0,84%	Corporate Communications
Manisha Narasimhan, Ph.D.	Hala Mirza
914.847.5126	914.847.3422
manisha.narasimhan@regeneron.com	hala.mirza@regeneron.com

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300556248.html

SOURCE Regeneron Pharmaceuticals, Inc.